Scatec ASA
Scatec ASA: Employee Share Purchase Programme 2025
Scatec ASA: Employee Share Purchase Programme 2025
Oslo, 16 June 2025: Scatec ASA (“The Company”) is continuing its Employee Share Purchase Programme established in 2019. The participants are offered to purchase shares with a subscription value of between NOK 10,413 and NOK 104,128. Employees are offered a price reduction of 25 percent of the subscription value in exchange for the shares being subject to a two-year lock-up period.
The subscription period will run from 16 June to 25 June 2025. The price per share will be based on the average volume-weighted share price on the Oslo Stock Exchange over the last five trading days during the subscription period. The allocation of shares will take place by the end of June 2025.
DNB will on behalf of the Company purchase Scatec ASA shares in the open market for onwards sale to participants under the programme.
For further information, please contact:
Andreas Austrell, SVP IR
andreas.austrell@scatec.com
+47 974 38 686
About Scatec
Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy in emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 6.2 GW in operation and under construction across five continents today. We are committed to grow our renewable energy capacity, delivered by our passionate employees and partners who are driven by a common vision of ‘Improving our Future’. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘SCATC’. To learn more, visit www.scatec.com or connect with us on LinkedIn.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Investeringsforeningen IA Invest16.6.2025 15:31:14 CEST | Pressemeddelelse
Investeringsforeningen IA Invest – Ombytningsforhold for fusion af afdeling Advice Capital Vision Fund med afdeling Advice Capital Global
Genmab A/S16.6.2025 15:28:29 CEST | Press release
Transactions in Connection with Share Buy-back Program
Danske Bank A/S16.6.2025 15:00:57 CEST | Press release
Danske Bank A/S, transactions by persons discharging managerial responsibilities
Danske Bank A/S16.6.2025 15:00:57 CEST | Pressemeddelelse
Danske Bank A/S, ledende medarbejderes transaktioner
Centessa Pharmaceuticals plc16.6.2025 15:00:37 CEST | Press release
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom